JSAM
SMMT icon

J. Safra Asset Management’s Summit Therapeutics SMMT Stock Holding History

J. Safra Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-83
Closed -$1.45K – 665
2025
Q4 		$1.45K Hold
83
– – ﹤0.01% 606
2025
Q3 		$1.72K Hold
83
– – ﹤0.01% 428
2025
Q2 		$1.77K Buy
+83
New +$1.89K ﹤0.01% 354

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

J. Safra Asset Management's SMMT Position: Q1 2026 in Review

J. Safra Asset Management sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 83 shares — an estimated $1.45K sold.

J. Safra Asset Management first reported a position in SMMT in Q2 2025 and held it in 3 quarters. The position peaked at $1.77K in Q2 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • J. Safra Asset Management reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
  • J. Safra Asset Management sold 83 Summit Therapeutics shares in Q1 2026, an estimated $1.45K.
  • J. Safra Asset Management first reported a position in Summit Therapeutics in Q2 2025 and held it in 3 quarters.
  • J. Safra Asset Management's Summit Therapeutics position peaked at $1.77K in Q2 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on J. Safra Asset Management's 13F filing for Q1 2026, filed 4 May 2026.